Verition Fund Management
CNTX icon

Verition Fund Management’s Context Therapeutics CNTX Stock Holding History

Verition Fund Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16,294
Closed -$32.7K – 3230
2024
Q2 		$32.7K Buy
+16,294
New +$28.1K ﹤0.01% 2831

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Verition Fund Management's CNTX Position: Q3 2024 in Review

Verition Fund Management sold out of Context Therapeutics (CNTX) in Q3 2024, closing a stake of 16,294 shares — an estimated $32.7K sold.

Verition Fund Management first reported a position in CNTX in Q2 2024 and held it in 1 quarter. The position peaked at $32.7K in Q2 2024. 42 funds tracked by Wall St. Rank hold CNTX as of Q3 2024.

  • Verition Fund Management reported no remaining Context Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Verition Fund Management sold 16,294 Context Therapeutics shares in Q3 2024, an estimated $32.7K.
  • Verition Fund Management first reported a position in Context Therapeutics in Q2 2024 and held it in 1 quarter.
  • Verition Fund Management's Context Therapeutics position peaked at $32.7K in Q2 2024.
  • 42 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2024.

Based on Verition Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.